Next Phase Newsletter

An investment firm based in Europe that provides private equity financing to early- and mid-stage human healthcare and life science companies has raised a new €100 million fund that closed in March 2016. The firm can allocate up to €7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm looks for companies that are based in Europe or the US.

The firm invests in innovative therapeutics, medtech and diagnostics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. For therapeutics, the firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have a solid animal data. For medical devices, the firm is also opportunistic and looks for devices that have a working prototype.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in Australia focuses on late stage therapeutics and medical devices that are past pre-clinical trials. Currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia.

The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is only interested in later stage technology at Phase II or later, and is particularly interested in peripheral blood-based colorectal cancer diagnostics. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in Europe has raised a new venture fund of €100 million and is looking to make 4-5 investments over the next 6 to 12 months. The firm could lead any investment up to $15M EUR but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider seed through IPO rounds. The firm seeks to invest in any European country and Israel.

The firm will look at a broad spectrum of products and services within the life science space. However, they will not consider drug discovery investments. They will consider anything related to medical devices, diagnostics, in-vitro diagnostics, healthcare IT. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and has proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital fund based in Toronto, Canada, looks to make investments in companies ranging from $1 – $5 million initially and up to $10 million over the life of the investment. The firm is looking for companies based within 1000 miles of Toronto. The firm makes approximately 2-3 new investments per year.

Within the life science space the firm is looking for medical device and diagnostics companies that have a clear path to FDA approval. The firm is open to all technology types and indications although they have experience working with assisted living devices and Imaging devices. The firm is looking for companies that have managed to demonstrate market interest in their product prior to investment.

The firm looks to be a very active investor in chosen companies and always pursues a board seat. The firm looks for strong experienced management teams and looks to bring their own entrepreneurial experience to aid in the growth and expansion of companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The in-licensing arm of an Asia-based pharma company with several US offices is seeking partnerships with companies based in the USA.

The firm seeks specialty biotech therapeutics in neurobiology, dermatology, respiratory, oncology and ophthalmology indications. The firm focuses on technology that are 2-3 years from the market and with a 505(b) (2) regulatory pathway. The firm will consider in-licensing and acquisitions in these specialty areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Japan-based corporate VC fund primarily makes early stage investments solely in the Life Sciences. The firm raised a new fund in 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, but at present has a primary focus on opportunities in the USA. The firm acts as a co-investor.

The fund focuses on therapeutic drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications and in products that are targeting Japan as a future market. The firm will consider products in all stages of development, but typically invests in products that are in pre-clinical and early-clinical stages.

The firm will only co-invest with other institutional investors in opportunities outside of Japan; companies backed solely by angel investors are not of interest. The firm prefers opportunities with a syndicate and/or lead investor in place. The firm typically requests board observation rights in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Massachusetts has two funds under management and is currently investing out of its second fund. The firm seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $2 million to $4million. The firm plans to invest in 2-4 companies over the next 12 months and prefers to invest in companies based in US or Canada.

The firm is currently looking for new investment opportunities in life sciences. The firm is interested in therapeutic platform technologies from an early stage of development, and is also interested in healthcare IT, device and diagnostic companies that are generating at least $2 million in revenue. The firm is currently not interested in single asset therapeutics or pre-revenue diagnostics/medical devices.

The firm generally seeks to invest in private companies. The firm has no specific requirements for the company’s management team, and sometimes takes a board seat when investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com